CAMKK2 and metabolic dysfunction-associated steatotic liver disease: Taken together, these findings clearly demonstrate attenuating CaMKK2 function with small molecule inhibitors is sufficient to not only inhibit, but reverse hallmarks of NAFLD in mice.